Accepted for Publication: July 23, 2013.
Published Online: October 7, 2013. doi:10.1001/jamaneurol.2013.4442.
Study concept and design: Lennon, Jones, Harper, McKeon.
Acquisition of data: Clardy, Dalmau, McKeon.
Analysis and interpretation of data: Clardy, Dalmau, Pittock, Renaud, Harper, Matsumoto, McKeon.
Drafting of the manuscript: Clardy, McKeon.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Clardy.
Obtained funding: Dalmau.
Administrative, technical, or material support: Clardy, Lennon, Dalmau.
Study supervision: Renaud, McKeon.
Conflict of Interest Disclosures: Dr Lennon receives royalties for technology relating to aquaporin 4 (AQP4) antibodies for diagnosis of neuromyelitis optica (NMO), is a named inventor on filed patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker, and receives research support from the National Institutes of Health (grant NS065829-01). Dr Dalmau’s work is supported in part by National Institutes of Health grant RO1NS077851, Fondo de Investigaciones Sanitarias (FIS, Spain, 11/01780), and Fundació la Marató de TV3. Dr Dalmau receives royalties from Athena Diagnostics for a patent for the use of Ma2 as an autoantibody test and licensing fees from Euroimmun for a patent for the use of N-methyl-D-aspartate receptor as an autoantibody test. Dr Pittock is a named inventor on filed patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker and receives research support from the National Institutes of Health (grant NS065829-01), the Guthy-Jackson Charitable Foundation, and Alexion Pharmaceuticals Inc. Dr McKeon receives research support from the Guthy-Jackson Charitable Foundation. No other disclosures were reported.